Phase 2 data presented at ASCO Genitourinary show disitamab vedotin (DV), a HER2‑targeting antibody‑drug conjugate, produced confirmed overall response rates above 50% in both HER2‑positive and HER2‑low cohorts of previously treated metastatic urothelial carcinoma. The trial reported median progression‑free survival of about 5.7 months and median overall survival near 17–20 months across cohorts. DV combines a HER2 antibody with MMAE as the payload and differs mechanistically from trastuzumab deruxtecan, currently the only approved HER2 ADC in urothelial cancer. Investigators highlighted comparable responses in HER2‑low tumors, widening the potential patient population. Sponsors said global development is accelerating beyond China; if validated in randomized studies, DV could expand targeted options in advanced bladder cancer where HER2 is an actionable biomarker.